The third recovered neuroblastoma program, NB-MYC, was only expressed in the high-risk patient sample (PD43255) and was characterized by lower expression of marker genes of differentiating chromaffin and neuronal cell types (Fig. 3d, f, Additional file 1: Fig. S3a), consistent with the undifferentiated pathology of high-risk neuroblastoma [33]. The gene discussed is MYC; the disease is neuroblastoma.